Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule
NCT00579410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85
Last updated 2011-03-22
Summary
The purpose of this research is to study the level of acid exposure above the gastroesophageal junction and the distal esophagus in patients with reflux symptoms using a capsule type acid measurement system. Patients with reflux symptoms are likely to have more acid reflux just above the junction of the stomach and the esophagus that may help to improve the diagnosis of gastroesophageal reflux disease (GERD). This may help better treat the reflux symptoms.
Conditions
- Esophagitis
- Inflammation
- Gastritis
- Abdominal Pain
- Heartburn
Sponsors & Collaborators
-
PriCara, Unit of Ortho-McNeil, Inc.
collaborator INDUSTRY -
VA Office of Research and Development
lead FED
Principal Investigators
-
Prateek Sharma, MD · Department of Veterans Affairs Medical Center of Kansas City
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2004-05-31
- Primary Completion
- 2009-10-31
- Completion
- 2009-10-31
Countries
- United States
Study Locations
More Related Trials
-
Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance
NCT01503476 ·Status: COMPLETED ·Phase: PHASE4
-
Validation of RDQ Questionnaire
NCT00291746 ·Status: COMPLETED ·Phase: PHASE4
-
Mechanisms Preventing Pharyngeal Reflux
NCT05696184 ·Status: RECRUITING ·Phase: NA
-
Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?
NCT01204931 ·Status: COMPLETED
-
Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
NCT02114216 ·Status: COMPLETED ·Phase: NA
-
Endoscopic Treatment of Gastroesophageal Reflux Disease
NCT05678491 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)
NCT00222170 ·Status: COMPLETED ·Phase: PHASE2
-
Measurement of Gastric Secretion by MRI Under Inhibition by ProtonPump Inhibitors in Healthy Subjects & in GERD Patients
NCT01212614 ·Status: COMPLETED ·Phase: NA
-
Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease
NCT01572974 ·Status: TERMINATED
-
Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus
NCT00573911 ·Status: COMPLETED ·Phase: PHASE1
-
Correlations Between Wireless pH Monitoring and Variation in Reflux Symptom Questionnaire, 7 Day Recall
NCT03407456 ·Status: COMPLETED
-
24 Hour Esophageal and Electrogastrography to Investigate the Mechanism of Reflux Esophagitis
NCT00154570 ·Status: UNKNOWN
-
Acetic Acid for the Detection of Esophageal Neoplasms
NCT04054713 ·Status: SUSPENDED ·Phase: NA
-
Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus
NCT01281618 ·Status: COMPLETED
-
Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
NCT03619811 ·Status: COMPLETED ·Phase: NA
-
Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes
NCT02477475 ·Status: COMPLETED
-
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
NCT00444236 ·Status: TERMINATED ·Phase: PHASE1
-
GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals
NCT02584751 ·Status: UNKNOWN ·Phase: PHASE1
-
Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD
NCT02699060 ·Status: COMPLETED ·Phase: NA
-
Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo
NCT00481949 ·Status: COMPLETED
-
The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients
NCT02149914 ·Status: UNKNOWN ·Phase: NA
-
The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis
NCT07079540 ·Status: COMPLETED ·Phase: PHASE3
-
Confocal Laser Microscopy in Non Erosive Reflux Disease
NCT00588939 ·Status: COMPLETED
-
Effectiveness of Physiologic Testing in PPI Non-Responders
NCT03202537 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
NCT00820079 ·Status: COMPLETED ·Phase: PHASE2